Literature DB >> 29554016

Protease-activated receptor 1 is implicated in irritable bowel syndrome mediators-induced signaling to thoracic human sensory neurons.

Cleo Desormeaux1, Tereza Bautzova1, Sonia Garcia-Caraballo2,3, Corinne Rolland1, Maria Raffaella Barbaro4, Stuart M Brierley2,3, Giovanni Barbara4, Nathalie Vergnolle1,5, Nicolas Cenac1.   

Abstract

Proteases and protease-activated receptors (PARs) are major mediators involved in irritable bowel syndrome (IBS). Our objectives were to decipher the expression and functionality (calcium signaling) of PARs in human dorsal root ganglia (DRG) neurons and to define mechanisms involved in human sensory neuron signaling by IBS patient mediators. Human thoracic DRG were obtained from the national disease resource interchange. Expression of PAR1, PAR2, and PAR4 was assessed by immunohistochemistry and quantitative reverse transcription PCR (RT-qPCR) in whole DRG or in primary cultures of isolated neurons. Calcium signaling in response to PAR agonist peptides (PAR-AP), their inactive peptides (PAR-IP), thrombin (10 U/mL), supernatants from colonic biopsies of patients with IBS, or healthy controls, with or without PAR1 or PAR4 antagonist were studied in cultured human DRG neurons. PAR1, PAR2, and PAR4 were all expressed in human DRG, respectively, in 20%, 40%, and 40% of the sensory neurons. PAR1-AP increased intracellular calcium concentration in a dose-dependent manner. This increase was inhibited by PAR1 antagonism. By contrast, PAR2-AP, PAR4-AP, and PAR-IP did not cause calcium mobilization. PAR1-AP-induced calcium flux was significantly reduced by preincubation with PAR4-AP, but not with PAR2-AP. Thrombin increased calcium flux, which was inhibited by a PAR1 antagonist and increased by a PAR4 antagonist. Supernatants from colonic biopsies of patients with IBS induced calcium flux in human sensory neurons compared with healthy controls, and this induction was reversed by a PAR1 antagonist. Taken together, our results highlight that PAR1 antagonism should be investigated as a new therapeutic target for IBS symptoms.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29554016     DOI: 10.1097/j.pain.0000000000001208

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  10 in total

1.  Serine proteases as luminal mediators of intestinal barrier dysfunction and symptom severity in IBS.

Authors:  Shoko Edogawa; Adam L Edwinson; Stephanie A Peters; Lakshmikanth L Chikkamenahalli; Wendy Sundt; Sara Graves; Sakteesh V Gurunathan; Margaret Breen-Lyles; Stephen Johnson; Roy Dyer; Rondell Graham; Jun Chen; Purna Kashyap; Gianrico Farrugia; Madhusudan Grover
Journal:  Gut       Date:  2019-03-28       Impact factor: 23.059

Review 2.  Inhibition of Serine Proteases as a Novel Therapeutic Strategy for Abdominal Pain in IBS.

Authors:  Lisse Decraecker; Guy Boeckxstaens; Alexandre Denadai-Souza
Journal:  Front Physiol       Date:  2022-05-19       Impact factor: 4.755

Review 3.  Epithelial-Neuronal Communication in the Colon: Implications for Visceral Pain.

Authors:  Sarah A Najjar; Brian M Davis; Kathryn M Albers
Journal:  Trends Neurosci       Date:  2020-01-23       Impact factor: 13.837

Review 4.  The enteric nervous system in gastrointestinal disease etiology.

Authors:  Amy Marie Holland; Ana Carina Bon-Frauches; Daniel Keszthelyi; Veerle Melotte; Werend Boesmans
Journal:  Cell Mol Life Sci       Date:  2021-03-26       Impact factor: 9.261

5.  Thrombin modifies growth, proliferation and apoptosis of human colon organoids: a protease-activated receptor 1- and protease-activated receptor 4-dependent mechanism.

Authors:  Morgane Sébert; Alexandre Denadai-Souza; Muriel Quaranta; Claire Racaud-Sultan; Sophie Chabot; Philippe Lluel; Nicolas Monjotin; Laurent Alric; Guillaume Portier; Sylvain Kirzin; Delphine Bonnet; Audrey Ferrand; Nathalie Vergnolle
Journal:  Br J Pharmacol       Date:  2018-08-07       Impact factor: 8.739

Review 6.  The neuro-glial coagulonome: the thrombin receptor and coagulation pathways as major players in neurological diseases.

Authors:  Shany G Gofrit; Efrat Shavit-Stein
Journal:  Neural Regen Res       Date:  2019-12       Impact factor: 5.135

7.  The Effect of Serine Protease Inhibitors on Visceral Pain in Different Rodent Models With an Intestinal Insult.

Authors:  Hannah Ceuleers; Nikita Hanning; Michelle De Bruyn; Joris G De Man; Heiko U De Schepper; Qian Li; Liansheng Liu; Steven Abrams; Annemieke Smet; Jurgen Joossens; Koen Augustyns; Ingrid De Meester; Pankaj J Pasricha; Benedicte Y De Winter
Journal:  Front Pharmacol       Date:  2022-06-02       Impact factor: 5.988

8.  Microbiota-neuroimmune cross talk in stress-induced visceral hypersensitivity of the bowel.

Authors:  Isabelle A M van Thiel; Wouter J de Jonge; Isaac M Chiu; Rene M van den Wijngaard
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2020-04-20       Impact factor: 4.052

Review 9.  Molecular Mechanisms of Microbiota-Mediated Pathology in Irritable Bowel Syndrome.

Authors:  Yoshiyuki Mishima; Shunji Ishihara
Journal:  Int J Mol Sci       Date:  2020-11-17       Impact factor: 5.923

10.  Olorinab (APD371), a peripherally acting, highly selective, full agonist of the cannabinoid receptor 2, reduces colitis-induced acute and chronic visceral hypersensitivity in rodents.

Authors:  Joel Castro; Sonia Garcia-Caraballo; Jessica Maddern; Gudrun Schober; Amanda Lumsden; Andrea Harrington; Shirdi Schmiel; Beatriz Lindstrom; John Adams; Stuart M Brierley
Journal:  Pain       Date:  2022-01-01       Impact factor: 6.961

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.